062
A PATIENT WITH WILLIAMS SYNDROME, JUVENILE POLYPS, AND PULMONARY AVMS
C.J. Gallione,1 C.L. Clericuzio,2 J.C. Fahl,3 D.A. Marchuk1
1Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC; 2Division of Genetics/Dysmorphology; 3Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA
This patient presented at age 3 with typical facial, cardiac, developmental, and behavioral features of Williams syndrome. Cytogenetic analysis showed normal 46, XY chromosomes and Fluorescence In Situ Hybridization (FISH) identified a deletion of the Elastin gene, confirming the clinical diagnosis. Family history was negative for Williams syndrome. At 4 years old, this patient was first hospitalized for bloody diarrhea. He underwent colonoscopy at 13 years for recurrent bloody stools. Multiple juvenile polyps were found in the ascending colon and rectum. Tissue testing for HNPCC by immunohistochemistry was negative. Persisting mild hypoxemia prompted CT angiography of the chest at 13 years which identified two pulmonary arteriovenous malformations (PAVMs). Head MRI with and without contrast at 13.5 years of age showed no evidence of cerebral AVMs. This patient has no history of epistaxis, no mucocutaneous telangiectasias, and no family history of HHT. The combination of multiple juvenile polyps and PAVMs is a common feature of JP-HHT syndrome. Sequence analysis of SMAD4 revealed a 302G>A, W101X mutation in exon 2. This is the most proximal mutation observed to date, as well as the first reported mutation, in the MH1 domain of SMAD4 in JP-HHT. The phenotype in this patient is due to the combination of the elastin deletion and the apparent loss of function mutation in SMAD4. At this point, it is unclear how this unique mutation in SMAD4 and the deletion of Elastin lead to this complicated phenotype.

063
BEYOND ENDOGLIN, ALK1, AND SMAD4: SEARCHING FOR NEW GENES FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA
C.J. Gallione,1 D. Perera,1 A. Burroughs,1 J.A. Richards,2 T.G.W. Letteboer,3 D. Rushlow,4 N.L. Prigoda,4 T.P. Leedom,1 A. Ganguly,2 J.K. Ploos van Amstel,3 C.J.J. Westermann,5 R.E. Pyeritz,6 D.A. Marchuk1
1Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA; 2Genetic Diagnostic Laboratory, 3DBG-Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands; 3HHT Solutions, Toronto Western Hospital, Toronto, Canada; 4St. Antonius Hospital, Nieuwegein, The Netherlands; 5Departments of Medicine & Genetics, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Mutations in Endoglin, ALK1, or SMAD4 account for up to 90% of all cases of HHT or related phenotypes (JP-HHT). Mutations in poorly understood regulatory regions of any of these three genes will account for some of these remaining cases. However, linkage of two unrelated families to a region on Chromosome 5 and another unrelated family to Chromosome 7 indicate that at least two other genes are involved in the pathogenesis of HHT. We are employing both a positional cloning and candidate gene approach to searching for additional HHT genes. We have assembled a cohort of 36 HHT patients for this mutation screen. All are ENG/ALK1/SMAD4 mutation negative by sequence analysis and ENG/ALK1 mutation negative by deletion screening. In one approach, we are systematically sequencing patients in our cohort for each of the genes mapping within the HHT3 and HHT4 intervals. Our second approach assumes that there may be more HHT loci than those for which we currently have provisional genome locations. Since each of the three identified genes are members of the TGF-β superfamily signaling pathway, and recent biochemical data implicates the BMP subfamily as the specific pathway directly involved in HHT pathogenesis, we have chosen to also sequence a series of genes encoding important members of these signaling cascades. This work is currently underway, and we will report the results of our screen. The identification of additional HHT genes will aid in the elucidation of the complexities of HHT pathogenesis.
Mutations in the activin A receptor type II-like 1 (ACVRL1) and endoglin (ENG) genes are known to cause Hereditary Hemorrhagic Telangiectasia (HHT). However, in about 15–20% of patients, mutation analyses of the coding regions of these genes failed to show mutations, which suggest either mutations in non-coding regions of these genes, or mutations in yet-to-be-identified genes are responsible for the disease in these patients. In this study, we sequenced the regulatory regions of both ACVRL1 and ENG genes. Our study group consisted of patients diagnosed with HHT according to the Curacao Criteria, in whom no causative mutation was found in the coding regions of ACVRL1 and ENG genes by sequencing or deletion/duplication testing. When available we performed linkage studies for the ACVRL1 or ENG regions and determined the affected gene. We sequenced approximately 9kb upstream of the ACVRL1 which includes exon 1 and the first two introns. We sequenced two segments, 600bp each, within the 8kb upstream of the ENG. We also sequenced the 3’ UTRs of both genes. We found previously reported and unreported variants. We will discuss the significance of each variant by comparisons to SNP databases, to our study group and by family segregation studies.

606
AN OPTIMIZED PROBABILISTIC METHOD TO IDENTIFY MUTATIONS THAT PREDISPOSE TO HEREDITARY HEMORRHAGIC TELANGIECTASIA

K. E. Vandezande
HHT Solutions Molecular Diagnostic Laboratory, Toronto Western Hospital, Canada

Mutations to (at least) three genes lead to HHT (ENG or ALK-1) and JHPT (MADH4). For several reasons, to detect mutations linked to HHT (JHPT) is a complex and resource-intensive undertaking: multiple genes, diverse mutation spectrum, and variable phenotypic presentation across individuals, even within the same family. Despite its cost and complexity, routine high-sensitivity identification of mutations offers the potential of both higher quality care and lower overall costs.1 Widespread clinical implementation of HHT molecular diagnosis requires rapid, reliable and cost-effective methods to identify mutations. Here I present a stochastic dynamic programming model meant to help a reference lab assemble, perform and analyze multiplex PCR reactions in a dynamically determined order that achieves the highest possible mutation discovery rate per unit cost (costs may be measured either by time or money). The model’s utility is shown to increase with sample volume, the number of distinct molecular assays required, and the degree of correlation between assay results. Computer simulations to order the 36 different assays used in our lab ranked more than 3.7×10^10 candidate strategies in less than two hours.

Reference
A Founder Effect for the ACVRL1 in Frame Del H97N98 Mutation in Italy: Haplotype Analysis and Epidemiological Data

C. Olivieri,1 F. Pagella,2 E. Matti,2 L. Lanzarini,2 S. Coccemancini,1 R. Dore,3 V. Vespro,4 C. Reduzzi,4 M. Grosso,5 G. Pongiglione,6 E. Boccardi,7 E. Matti,3 J.K. Ploos van Amstel,2 G. Manfredi,3 K.A. Harradine,1 C. Danesino*1

1Medical Genetics, University of Pavia, Pavia; 2ENT Unit, Fondazione IRCCS Policlinico S Matteo, Pavia; 3Cardiology Institute, Fondazione IRCCS Policlinico S Matteo, Pavia; 4Radiology Institute, Fondazione IRCCS Policlinico S Matteo, Pavia; 5Radiology Unit, Santa Croce Hospital, Crema; 6Cardiovascular Department, Istituto G. Gaslini Children’s Hospital, Genova; 7Interventional Neuroradiology Unit, Niguarda Hospital, Milan; 8Gastroenterology Unit Ospedale Maggiore, Crema; 9Medical Genetics, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy

A Founder Effect for specific mutations observed with high frequency was suggested in the Netherlands Antilles (ENG: c.1238G>T; g.IVS1+1g>a), France (ACVRL1: c.1112_1113dupG) and Denmark (ENG: c.360C>A). We observed in the North Italian county of Bergamo the same mutation (ACVRL1: c.289_294 del CACAAC) in 9 families with 37 affected subjects, from a population for the county of 1,021,700 in 2004. All the families are unrelated for at least 4 generations and come from a limited region east of the town of Bergamo. Other HHT families not carrying this mutation are known in the same area. To the best of our knowledge, this mutation has been observed only in these families, at variance with the previously quoted mutations, which have been found in different populations. The mutation we studied causes the in frame deletion of His 97 and Asn 98, which are conserved residues in orthologous genes. In our series of more than 120 index cases we were able to found, till now, 86 mutations. ACVRL1 harboured 62/86 mutations and 9/62 (14.5%) were represented by the c.289_294 del CACAAC. Preliminary results suggests a founder effect for these families. After completing the study of the families by determining the ancestral haplotype carrying the mutation by microsatellite analysis, we intend to apply the formula:

$$\frac{\log (1-\delta)/(1-p_\theta)}{\log (1-\theta)}$$

to calculate how long ago this mutation occurred (Brusgaard et al (2004)). Identification of this haplotype will be relevant for epidemiological studies on HHT in the region of Bergamo.
and/or unlinked genetic modifiers. ENG and ACVRL1 both encode proteins of the TGFβ pathway, and the influence of polymorphic variation in TGFβ signalling components and TGFβ genetic modifiers (TGFβMs) has previously been documented for cardiovascular development, disease and cancer, in mice and humans. We examined whether variations in genes encoding components of the TGFβ signalling pathway and/or TGFβ modifier genes influence the phenotype of HHT. SNP analysis was performed using the Illumina Bead array in 736 subjects (486 HHT mutation carriers and 250 related controls). 768 SNPs were selected representing haplotypes for 74 known TGFβ signalling pathway genes and 6 genes within TGFβMs, 29 genes within TGFβM3. Patient samples were stratified according to the presence or absence of different manifestations of HHT (PAVM, CAVM, HAVM), and the data are being analyzed using a variety of analytical tools, including genetic association, parametric and nonparametric linkage analysis and sib pair analysis. Preliminary results will be available for presentation. Identification of genetic modifier genes that influence HHT severity will lead to a better understanding of disease mechanisms that could lead to novel therapies, and may result in better risk assessment for the onset of life-threatening symptoms.

**070 GENOTYPE AND EPISTAXIS (ONSET AND FREQUENCY)**

St. Antonius Hospital, Nieuwegein, The Netherlands

*Introduction.* HHT-1 and HHT-2 have a different phenotype regarding visceral AVMs and (muco-) cutaneous telangiectasia. Three small studies (Berg, Kjeldsen, Bayrak) yield conflicting results about epistaxis. This study concerns the onset and frequency of nosebleeds in a large number of patients and addresses the relation to genotype, gender and race. *Methods.* A standard questionnaire has been used in all patients at their first visit to the hospital. These were studied retrospectively. *Results.* There were 294 patients with HHT-1, 105 Afro-Caribbean and 189 Caucasians, 123 men (42%). 173 Patients had HHT-2, all Caucasians, 72 men(42%). Patients with HHT-1 were younger (37.7 vs 44.8 years; *p*<.005). The onset of nosebleeds was significantly earlier in HHT-1(*p*<.001), as well in men as in women. At age 20, 80% of patients with HHT-1 had epistaxis and only 54% of patients with HHT-2. The point-prevalence in the entire population was respectively 95% and 91%. The frequency of epistaxis increased significantly with age in men with HHT-1 (*p*<.001) and HHT-2(*p*<.01), but not in women. The age-related frequency did not differ between HHT-1 and HHT-2. The onset of nosebleeds was earlier in Caucasians than in Afro-Caribbeans with HHT-1(*p*<.05), but the frequency did not differ. *Comment.* Clinical diagnosis is more difficult in HHT-2 than in HHT-1 at young ages. HHT-1 has an earlier onset of epistaxis, but age-related frequency is the same as in HHT-2. Frequency of nosebleeds increases significantly with age only in men. Genotype-phenotype studies should be stratified for gender.

**071 POTENTIAL EFFECTS OF SILENT VARIANTS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA**

J. McDonald, R. Mao, P. Bayrak-Toydemir
1. ARUP Institute for Clinical and Experimental Pathology; 2. Department of Radiology, University of Utah; 3. Department of Pathology, University of Utah; Salt Lake City, UT, USA

The genetic heterogeneity of HHT, with two known genes, does not explain the variable clinical symptoms and manifestations routinely seen within families. Neither ENG nor ACVRL1 mutations seem to correlate with the severity of the phenotype. This wide range of clinical presentation and the lack of an obvious genotype-phenotype correlation suggest effects of genetic modifiers on the HHT phenotype. However, it is unknown if the clinical variability is due to silent variants in known HHT genes or due to other modifier genes. In this study we analyzed the potential effects of polymorphisms in the HHT genes by sequencing the coding regions and exo-introns of HHT genes. Our study group consisted of 200 HHT patients in whom mutations were found in ENG or ACVRL1 and 96 healthy individuals. As expected, we found some sequence variants in both groups with similar frequencies. However, since some sequence changes were observed only in the patient group, we speculate that these variants might be associated with the variability of the clinical phenotype. In addition, via segregation analyses, we show that some previously reported mutations are not disease causing changes. We will present and discuss the significance of some variants seen in HHT patients with known mutations.

**072 THE ACTIVIN RECEPTOR-LIKE KINASE 1, ALK1, AND BMPRII COOPERATE TO PHOSPHORYLATE ENDOGLIN IN RESPONSE TO BMP9**

‘Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine; 2. Department of Cell Biology, University of Alabama, Birmingham, AL; 3. Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

In humans, mutations in TGFβ-family signaling proteins are responsible for inherited vascular diseases. Mutations in endoglin and ALK1 result in the autosomal dominant vascular dysplasia, hereditary hemorrhagic telangiectasia. In addition, genetic data suggest a functional relationship between ALK1, BMPRII, and endoglin, because mutations in BMPRII, ALK1 and less frequently, endoglin, are associated with primary pulmonary hypertension. However, the molecular mechanisms underlying these vascular diseases remain poorly characterized. We provide evidence that ALK1 and BMPRII physically associated, and that a functional consequence of this interaction was threonine phosphorylation of endoglin by ALK1. Endoglin phosphorylation by ALK1 was specifically enhanced in the presence of BMPRII. This enhancement was independent of the BMPRII kinase activity.
Additionally, BMPRII was able to rescue Smad activity by a Smad binding-defective ALK1 receptor, suggesting a novel kinase-independent role for BMPRII in ALK1 signaling. Endoglin was phosphorylated in response to ligand stimulation of particular type I and type II receptor pairs. BMP9 specifically induced endoglin phosphorylation through the ALK1/BMPRII complex, while TGFβ1 preferentially utilized the ALK5/TβRII complex. BMP9, but not BMP10 inhibited endothelial cell tube formation in collagen gels. This effect was partially reversed by endoglin, but not by a threonine phosphorylation-defective endoglin mutant. Previous studies suggest that threonine phosphorylation of endoglin plays a role in the endothelial cell response to ALK1 activation. The current study supports the view that BMP9 is a physiologic ligand for the ALK1/BMPRII complex that regulates endothelial cell organization via the phosphorylation of endoglin.

**073 CHARACTERIZATION OF THE PROMOTER REGION OF ALK1, THE TARGET GENE FOR HEREDITARY HAEMORRHAGIC TELANGiectasia TYPE 2**

E.M. Garrido-Martin,1 A. Fernandez-L,1 C.P. Vary,2 L.M. Botella, C. Bernabeu1

1Centro de Investigaciones Biologicas, CSIC, and Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain; 2Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA

ALK1 is a type I TGF-β receptor predominantly expressed in endothelial cells. Heterozygous mutations in the gene coding for ALK1 (ACVRL1), give rise to HHT type 2. Since the pathogenic mechanism of HHT2 is due to ALK1 haploinsufficiency, the study of the regulation of ALK1 gene expression is critical to correct the disease. As a first step to ascertain the factors involved in ALK1 transcriptional regulation, we report here the sequence and characterization of its promoter region. We have sequenced a 1247 bp fragment of genomic DNA containing the theoretical transcription start site and part of the first exon. This sequence was subjected to an in silico analysis with different algorithms, to find putative transcription factor binding sites. The 5′ region of ALK1 lacks TATAA and CAAT boxes, but contains a G/C rich region with multiple consensus sequences for Sp1 transcription factor. To assess whether Sp1 was a basal transcription factor for ALK1, different promoter constructs were generated and inserted into the pGL2 reporter. Schneider cells lacking Sp1 were transiently transfected with these constructs in the absence or presence of Sp1. Without Sp1 no significant ALK1 promoter activity could be detected, whereas Sp1 cotransfection increased the promoter activity up to 15 fold. These results suggest that Sp1 is involved in the basal transcription of ALK1. Current studies in progress are addressing the identification of other transcription factors able to upregulate ALK1 gene expression, which may be used to compensate for HHT2 haploinsufficiency.

Acknowledgements: We thank Dr. Jonathan Berg for providing the ALK1 genomic fragment (Berg et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet. 1997 61:60-7).
tic endothelial cells (MAEC) from endothelial sprouts derived from aorta rings from Eng$^{+/+}$ C57BL/6 and wild type mice. Western blot analysis revealed that endoglin expression was reduced by 50% in Eng$^{+/+}$ MAEC. The effects of endoglin heterozygosity on cellular proliferation were tested by determining the increase in cell number. Eng$^{+/-}$ proliferated significantly slower than Eng$^{+/+}$ MAEC. Flow cytometry analysis revealed a greater percentage of Eng$^{+/+}$ cells arrested in G0/G1. Endothelial cell migration was analysed by two independent techniques. Eng$^{+/-}$ MAEC, in a scratch wound assay, migrated a shorter distance than Eng$^{+/+}$ cells. Similarly, the number of migrated cells, in a Boyden chamber, was lower in Eng$^{+/-}$ than Eng$^{+/+}$ MAEC. Collagen and fibronectin synthesis, assessed by [1H]proline incorporation and Western blot respectively, was significantly greater in Eng$^{+/-}$ compared to Eng$^{+/+}$ MAEC. Given that VEGF is a central mediator of endothelial cell proliferation and migration, its basal levels were quantified by ELISA. They were significantly reduced in Eng$^{+/-}$ versus Eng$^{+/+}$ cells. The mitogenic and chemotactic effects of VEGF on endothelial cells are NO-dependent and necessitate normal eNOS expression. Eng$^{+/-}$ MAECs displayed significantly reduced eNOS levels relative to Eng$^{+/+}$ cells. These data reveal the importance of endoglin in modulating important biological properties related to angiogenesis.

076 ENDOGLIN HAPLOINSUFFICIENCY MODIFIES BIOLOGICAL PROPERTIES IN DERMAL FIBROBLASTS

M. Pericacho, M. Prieto, J.M. López-Novoa, A. Rodriguez-Barbero
Instituto Reina Sofia de Investigación Nefrológica, Dpto de Fisiología y Farmacología, Universidad de Salamanca, Salamanca, Spain

Endoglin is a TGF-β co-receptor expressed mainly on endothelial cells involved in vascular remodelling, angiogenesis and fibrosis. Mutations in the coding region of CD105 gene are associated with HHT1, a vascular disorder characterized by multisystemic vascular dysplasia. The main body of endoglin studies have been realized in endothelial cells, however endoglin is expressed in other cell types and implicates in many physiological processes. Thus, we hypothesized that endoglin expression in other cell types may have different properties. The aim of the present study was to evaluate the role of endoglin on cell proliferation and migration in dermal fibroblasts from endoglin heterozygous (Eng$^{+/-}$) mice. We generated primary cultures of murine dermal fibroblasts, and characterized them by immunocytofluorescence by the absence of cytokeratin and the expression of structured smooth muscle actin filaments, a characteristic of myofibroblasts, activated form of fibroblasts. Western blot analysis revealed that endoglin expression was reduced by 50% in Eng$^{+/-}$ fibroblasts. The rate of cell growth, analyzed by cell cycle studies, PCNA expression and crystal violet assays, was faster in Eng$^{+/-}$ fibroblasts than in control cells. In the same way, migration stimulation was observed in Eng$^{+/-}$ cells measured by both, a multichannel wounding and a transwell system. In endothelial models shown by other authors, Eng$^{+/-}$ cells have deficient migration and proliferation. Whereby our data reveal the importance of endoglin in modulating proliferation and migration in this model, and could show a cell-type dependent role of endoglin.

077 ENDOGLIN OVEREXPRESSION IN SPINDLE CARCINOMA CELL LINE SUPPRESSES TUMOROGENICITY IN SCID MICE

E. Pérez-Gómez, C. Vary, C. Bernabéu, M. Quintanilla
1Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain; 2Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine; 3Centro de Investigaciones Biológicas, CSIC, Madrid, Spain

The multistage skin cancer model in mice provides continuing insight on fundamental aspects of tumor evolution. In this model, the squamous to spindle cell carcinoma conversion is the latest stage in tumorigenesis, an event associated with shedding of membrane-bound endoglin (mEng) and production of soluble endoglin (sEng). Thus, intact mEng can not be detected in spindle carcinoma cell lines, such as CarC, but these cells produce sEng which is releases into the extracellular medium. In order to study the effect of mEng expression on the phenotype of spindle carcinoma cells, we have obtained CarC cell transfectants stably expressing a human L- or S-endoglin. Expression of L-endo, but not of the S-endo, reduced Smad 2, 3 signalling but did not affect the TGF-β cell proliferative response. When the cell lines were transplanted onto immunocompromised SCID mice, L-endo transfectants but not S-endo transfectants showed longer tumor latencies with respect to control cells. Furthermore, L-endo CarC tumors did not express mEng protein while the shorter mEng isoform was easily detected in S-endo CarC tumors by Western-blotting and immunohistochemistry. These results suggest that L-endoglin is able to suppress the tumorigenicity of spindle carcinoma cells. The structural motif responsible for this effect appears to reside in the cytoplasmic tail, the only domain which is different between L- and S-isoforms.

078 ENDOGLIN HETEROZYGOUS MICE DEVELOP MORE SEVERE COLITIS THAN THEIR NORMAL LITTERMATES

1Molecular Structure and Function Programme, Hospital for Sick Children; 2Heart and Stroke Levar Center of Excellence; 3Department of Immunology, University of Toronto, Canada; 4Laboratory of Immunophysiology, Brigham & Women’s Hospital, Boston MA; 5Anatomisches Institut, Johannes Gutenberg-Universität Mainz, Germany

We investigated whether Endoglin heterozygous (Eng$^{+/-}$) mice, predisposed to HHT1 and telangiectasia, would be more susceptible to a model of inflammation associated...
with leukocyte extravasation. We treated mice with 3% dextrane sulfate sodium (DSS) in their drinking water for 5 days, to trigger an inflammatory bowel disease. Mice were examined daily and sacrificed at either day 5, or between days 8-12 and 19-21 and the entire colon processed for histology. Corrosion cast and scanning electron microscopy (SEM) of colonic vessels were also performed on separate groups of mice at days 8-9. Both Eng−/− and Eng+− mice developed severe colitis, peaking at days 8-10. Symptoms were worse in Eng−/− mice: weight loss, diarrhea and fecal blood. Histological analysis showed more leukocyte infiltration and crypt damage in Eng−/− mice. SEM revealed dilated colonic vessels in both groups of mice. Our studies reveal that Eng+− mice develop more severe colitis than control littermates. We will characterize the infiltrates to ascertain if HHT mice display functionally impaired subsets of leukocytes. We also need to determine if the increased level of infiltration in the colon of HHT mice can be attributed to more focal structural dilations of microvessel segments (microangectasia) that would facilitate leukocyte transmigration.

**079 VASCULAR ENDOTHELIAL GROWTH FACTOR AND TRANSFORMING GROWTH FACTOR IN CHILDREN WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA**

P. Giordano, G.C. Del Vecchio, G. Di Bitonto, M. Altomare, E. Altavilla, A. Nigro, G.M. Lenato, D. De Mattia

Dipartimento di Biomedicina dell’Età Evolutiva, ‘HHT Inter-departmental Centre, University of Bari, Italy

High levels of vascular endothelial growth factor (VEGF) and transforming growth factor (TGF) have been reported in adults affected by hereditary hemorrhagic telangiectasia (HHT). Aim. To estimate VEGF and TGF-β1 serum levels in children with HHT and to correlate them to the presence or absence of arteriovenous malformations (AVM) and to genetic mutations. Materials and Methods. We have enrolled 17 children with HHT (14 F, 3 M, median age 9 y) and 17 healthy control subjects. We have researched AVM with imaging methods and we have estimated ENG and ALK-1 with molecular analysis. VEGF and TGF-β1 serum concentrations were determined by standard ELISA. We have subdivided patients into two groups based on the presence or absence of AVM. Data were expressed as median, minimum, maximum and percentage and analysed by using test U of Mann-Whitney and Chi square test. Results. AVMs were present in 11 patients, in 5 AVMs were absent and in 1 were not evaluated. There was not significant difference into VEGF levels between patients (median 218 pg/mL, minimum 50 pg/mL, maximum 500 pg/mL) and controls (median 290 pg/mL, minimum 71 pg/mL, maximum 500 pg/mL) and into TGF-β1 levels between patients (median 11.2 ng/mL, minimum 10 ng/mL, maximum 20 ng/mL) and controls (median 14.6 ng/mL, minimum 7.2 ng/mL, maximum 20.8 ng/mL). Among patients serum levels of VEGF in those with AVM (median 250 pg/mL, minimum 85 pg/mL, maximum 500 pg/mL) were significantly higher than those without AVM (median 165 pg/mL, minimum 50 pg/mL, maximum 200 pg/mL). No difference for TGF-β1 levels was found in these subgroups of patients. Finally no difference was noted for VEGF and TGF-β1 levels among 6 patients with ENG and 9 patients with ALK-1; in 2 patients mutation was not note. Conclusions. VEGF is increased not in all children with HHT but in those with AVM.

**080 EVALUATION OF IMMUNE PARAMETERS IN CHILDREN WITH HHT**


1 Department of Internal Medicine, Immunology and Infectious disease, 2National Institute of Gastroenterology, Castellana Grotte, 3HHT Interdepartmental Center, Unit of Pediatrics, 4Department of Internal Medicine and Public Health, University of Bari, Italy

Previously, our group evidenced certain immune deficit parameters in adults with HHT. In particular, our data demonstrated the occurrence of a Th1-type response ablation and of innate immune response depression. In order to evaluate whether these deficits are congenital, we successively investigated immune responsiveness in children with HHT. Patients were divided into ENG-mutated, ALK1-mutated and non-HHT-epistaxis-affected subgroups. Regarding T-cell subsets, B-cells and NK-cells, frequencies ranged within normal values in all subgroups when compared to healthy age-matched controls. Moreover, T-regulatory cell frequencies did not show any significant alterations. In addition, percentages of cytokine (IL-10, TNF-β)-positive lymphocytes and monocytes were normal in all subgroups. The only statistically significant parameter involved was related to polymorphonuclear cell oxidative burst which was significantly reduced in ENG-mutated children, but not in their ALK1-mutated counterparts. Overall, these findings suggest that immune deficits in HHT are not congenital but rather acquired with age, more likely due to a more precocious immune senescence.

Reference

**081 UPTAKE OF GENETIC TESTING/COUNSELLING FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) IN AT-RISK RELATIVES OF INDIVIDUALS WITH ENG AND ALK-1 MUTATIONS**

R. Klatt

Division of Clinical & Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Canada

Clinical genetic testing for HHT has been available since November 2003. One of the main benefits of testing, if informative in a proband, is to clarify uncertain diagnoses in at-risk relatives. Anecdotally, however, it appears that a significant number of at-risk relatives do not pursue gene-
tic counselling and testing. Methods. We performed a retrospective review of genetics charts of 53 at-risk individuals (22 males and 31 females) from 12 families where the proband was initially counselled and tested in the Genetics Clinic at the Hospital for Sick Children, an academic medical centre. We encouraged the uptake of genetic counselling and testing in at-risk relatives by suggesting that probands share a copy of the detailed counselling letter they received with first-degree relatives and by providing the contact information for a genetic counsellor specializing in HHT. We also received a number of referrals for at-risk relatives, mainly through the Toronto HHT Centre. We did not attempt to contact relatives directly. Results. Three of 22 siblings of an affected individual with a disease-causing mutation in either ENG or ALK-1 pursued genetic counselling and testing. Sixteen of 27 children of an affected person with a mutation in ENG or ALK-1 pursued genetic testing and counselling. Four individuals were more distantly related. We will also report on genetic test results and symptomaology in the relatives. Conclusions. Establishing a genetic counselling and testing for at-risk relatives is needed.

082 HEREDITARY HEMORRHAGIC TELANGIECTASIA IN CHILDREN: A SINGLE CENTER STUDY

N. Bevers, J.J. Mager, W. Balemans, C.J.J. Westermann

Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands

Background. Hereditary hemorrhagic telangiectasia (HHT) affects approximately 1:5000 in the Netherlands. Diagnosis in children may be difficult, because manifestations of the disease develop with increasing age. Objective. This study describes general characteristics and manifestations of HHT in patients under 18 years of age. Methods. From the database of the national referral centre in the Netherlands we selected all individuals under the age of 18 years from 64 HHT families. We studied 198 children. Results. The analysis revealed 51 patients (mean age 11.6 years; 55% boys) with a genetic diagnosis. ENG mutation (HHT1) was identified in 41 children (mean age 11.5 years; 54% boys), of whom 17 had definite HHT according to the Curaçao criteria. Nine patients with ALK-1 mutation were identified (mean age 12.7 years; 56% boys); 2 of them had a definite clinical diagnosis. One child had a SMAD4 mutation. Overall, in 27 children (mean age 12.9 years; 41% boys) a definite clinical diagnosis of HHT could be made. Capillary microscopy was often helpful in establishing the criterion telangiectases. PAVM were detected in 21 patients and occurred more often in HHT1 than HHT2. CAVM were detected in 3 of 35 children screened for CAVM and all 3 were suffering from epilepsy. Conclusions. Establishing a clinical diagnosis of HHT in children is more difficult in HHT2 than HHT1. Without DNA-testing, the diagnosis would have been missed in 24 of 41 HHT1 and 7 of 9 HHT2 children. The study confirms that PAVM occur more often in HHT1.

083 DESCRIPTION AND PRELIMINARY RESULTS OF A NEW EXERCISE STRESS TEST FOR MEASURING FUNCTIONAL CAPACITY OF PATIENTS WITH DIFFUSE PULMONARY ARTERIOVENOUS MALFORMATIONS

J.J. Murphy, P. Pierucci, K. Henderson, J.T. Fahey, D. Chyun, R.I. White Jr

Yale University School of Medicine; Yale University School of Nursing, New Haven, CT, USA

Background. To describe a new method for functional assessment of patients with diffuse pulmonary arteriovenous malformations (PAVM), using a novel exercise stress test. Methods & Materials. Over the past three years, 25 cardiopulmonary exercise stress tests (EST) were performed on 17 individuals (9 pediatric & 8 adult) with diffuse PAVM. The ESTs were performed in the Pediatric Cardiology Exercise Lab using a progressive incremental protocol for a cycle ergometer. Baseline heart rate, electrocardiogram, and oxygen saturation data were obtained with the individual seated on the cycle. The exercise intensity started at 30 watts and increased by 30 watts every two minutes, while continuous heart rate and oxygen saturation data was obtained. The EST was ended when the individual’s heart rate reached 90% of predicted maximum or when the individual could not continue due to leg fatigue, shortness of breath, or arrhythmia. During the recovery period, heart rate and oxygen saturation data were monitored until the heart rate and saturation were within 10% of the baseline. Results. Exercise limitation was associated with rapid rise in heart rate and fall in oxygen saturation. No complications were associated with EST and in the patients serial testing, the results were reproducible.

Table.

<table>
<thead>
<tr>
<th></th>
<th>Age &lt;18</th>
<th>Age ≥18</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=9 (4 male)</td>
<td>N=8 (2 male)</td>
</tr>
<tr>
<td>Baseline HR</td>
<td>107±12</td>
<td>86±12</td>
</tr>
<tr>
<td>Baseline O. sat</td>
<td>0.80±0.10</td>
<td>0.89±0.09</td>
</tr>
<tr>
<td>Min O. sat</td>
<td>0.78±0.13</td>
<td>0.70±0.14</td>
</tr>
<tr>
<td>Min to peak</td>
<td>5.8±1.6</td>
<td>8±2</td>
</tr>
<tr>
<td>Max watts</td>
<td>87±23</td>
<td>124±36</td>
</tr>
<tr>
<td>Weight percentile</td>
<td>0.53±0.27</td>
<td></td>
</tr>
<tr>
<td>Height percentile</td>
<td>0.63±0.31</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions. Cardiopulmonary exercise stress testing provides a noninvasive, functional assessment of individuals with diffuse PAVM without exposure to radiation.
M. Grosso, L. Lanzarini, E. Boccardi, G. Pongiglione, S. Ceccomancini, L. Reduzzi, E. Boccardi, C. Danesino, C. Olivieri, S. Ceccomancini, E. Buscarini, C. Olivieri, E. Matti, F. Pagella, V. Portugalli, E. Matti, G. Pongiglione, V. Vespro, Crema; Crema; Radiology Institute, Fondazione Policlinico S Matteo, Pavia; ‘Medical Genetics, University of Pavia, Pavia; ‘ENT Unit, Fondazione Policlinico S Matteo, Pavia; ‘Cardiology Institute Fondazione Policlinico S Matteo, Pavia; ‘Gastroenterology Unit Ospedale Maggiore, Crema; ‘Radiology Unit, Santa Croce Hospital, Cuneo; ‘Cardiovascular Department, Istituto G. Gaslini Children’s Hospital, Genova; ‘Interventional Neuroradiology Unit, Niguarda Hospital, Milan, Italy

Screening algorithm for pulmonary arteriovenous malformations (PAVMs) in hereditary haemorrhagic telangiectasia (HHT) is based on the combined use of contrast echocardiography and anteroposterior chest radiograph, followed by chest CT if at least one test is positive. An alternative is to screen directly by chest CT. Some authors described CT techniques for evaluating PAVMs in HHT patients, with conventional, or spiral CT units, but none described scanning and post-processing techniques with 16-64 multidetector CT units. We describe protocols of 16 detector spiral CT used in the pretherapeutic evaluation of PAVMs. Main characteristics are: sub-millimetric collimation that allowed demonstration of millimetric vessels; no intravenous contrast medium; high spatial resolution in all axis with isotropic multiplanar reconstructions mainly in coronal and sagittal views that enhance topographic relations; scanning requires only one breath-hold of about 10 sec; automatic modulation of radiation doses tailored for each patients; reduction of the one breath-hold of about 10 sec; automatic modulation of radiation doses; no intravenous contrast medium; high spatial resolution in all axis with isotropic multiplanar reconstructions. We considered lobar and segmental location, peripheral (30 mm or less from pleural line) or central site (more than 30 mm), size of the aneurysms, diameter of the vascular pedicles. Patients. among subjects with clinical and genetic evidence of HHT, 56 patients had positive US test and CT evidence of PAVMs. Results. 123 PAVMs have been recognized; 77 in right lung, 46 in the left; 40 in upper lobes, 25 in medium lobes and lingula, 58 in lower lobes. Right upper lobe was affected more frequently (30 PAVMs) than left upper lobe (10 PAVMs). Only 11/123 PAVMs were in central location (7 in lower lobes). 40 PAVMs were less than 3 mm (21 in upper lobes, 15 in lower), 48 PAVMs more than 3 mm diameter (14 in upper lobes, 24 in lower); 34 PAVMs more than 10 mm (18 in lower lobes). Conclusions. Some results are unexpected on the basis of the letterature: prevalence for the right lung, lower involvement of left upper lobe, mild prevalence of the small PAVMs for upper lobes and of the medium/large PAVMs for lower lobes.

085 ANATOMIC LOCATION AND MORPHOLOGY OF PULMONARY ARTERIOVENOUS MALFORMATIONS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA EVALUATED IN MULTIDECTION COMPUTED TOMOGRAPHY


‘Radiology Institute, Fondazione Policlinico S Matteo, Pavia; ‘Radiology Unit, Ospedale Maggiore, Crema; ‘Medical Genetics, University of Pavia, Pavia; ‘ENT Unit, Fondazione Policlinico S Matteo, Pavia; ‘Cardiology Institute Fondazione Policlinico S Matteo, Pavia; ‘Gastroenterology Unit Ospedale Maggiore, Crema; ‘Radiology Unit, Santa Croce Hospital, Cuneo; ‘Cardiovascular Department, Istituto G. Gaslini

Aim. To demonstrate safety and efficacy of embolization to treat localized pulmonary arteriovenous malformations (PAVMs). To emphasize technical aspects of the procedure relevant to successful embolization. To define clinical indications for embolization of PAVMs. Materials and Methods. All consecutively seen patients treated with embolization for localized PAVMs have been enrolled in the study. Clinical presentation (dyspnea, previous history of paradoxical embolism) and characteristics of treated PAVMs (single or multiple, location, diameter of the feeding artery and angioarchitecture (simple or complex) have been recorded. Specific information including number of PAVMs, number of coils and per-procedural complications has been obtained. Clinical and imaging follow-up using multidetector computed tomography has also been performed. Results. Forty-two patients (26 women and 16 men, mean age 45 y.o.) including 36 with hereditary hemorrhagic telangiectasia have been embolized. Twenty two patients (53%) presented with dyspnea and 12 (29%) had previous paradoxical embolism prior to embolization. A total of 99 PAVM (mean 2.3 per patient) have been treated using 530 coils (mean 12.6 per patient).
between 2001 and 2005, screening MRI’s were performed, ranging from 0.0015% to 0.08% of live births. There are no reports of association with hereditary hemorrhagic telangiectasia caused by mutations in the homeobox gene EMX2. There are familial cases. A subset of the familial cases appear to be associated with warfarin exposure, cytomegalovirus infection, and tube- rous sclerosis. Most cases appear to be sporadic, but some are familial. A subset of the familial cases appear to be caused by mutations in the homeobox gene EMX2. There are no reports of association with hereditary hemorrhagic telangiectasia (HHT). Information regarding frequency is scarce, ranging from 0.0015% to 0.08% of live births. Between 2001 and 2005, screening MRI’s were performed on 149 patients in our center. 3 of 149 had schizencephaly, for a prevalence of 0.67%, which is 8.4 to 447 times that expected. The frequency of associated symptoms and complications (seizures, developmental delay, and paraparesis) were similar to those previously reported. Given that schizencephaly has a genetic basis in some patients, and that EMX2 does not account for all, we believe it is plausible that one or more of the mutations causative for HHT may cause schizencephaly, perhaps due to fetal cerebral vascular maldevelopment. Evaluation of cerebral screening data from other centers is warranted, and if our findings are confirmed, genetic correlation should follow.

Schizencephaly is a brain development abnormality in which a gray matter-lined cleft connects the cerebral cortex with the ventricles. The pathophysiology is thought to be an abnormality of neuronal migration during fetal life, although it has also been postulated that in utero ischemic insult may be the underlying cause. A variety of associations have been noted, including drug abuse, prenatal warfarin exposure, cytomegalovirus infection, and tuber- rous sclerosis. Most cases appear to be sporadic, but some are familial. A subset of the familial cases appear to be caused by mutations in the homeobox gene EMX2. There are no reports of association with hereditary hemorrhagic telangiectasia (HHT). Information regarding frequency is scarce, ranging from 0.0015% to 0.08% of live births. Between 2001 and 2005, screening MRI’s were performed on 149 patients in our center. 3 of 149 had schizencephaly, for a prevalence of 0.67%, which is 8.4 to 447 times that expected. The frequency of associated symptoms and complications (seizures, developmental delay, and paraparesis) were similar to those previously reported. Given that schizencephaly has a genetic basis in some patients, and that EMX2 does not account for all, we believe it is plausible that one or more of the mutations causative for HHT may cause schizencephaly, perhaps due to fetal cerebral vascular maldevelopment. Evaluation of cerebral screening data from other centers is warranted, and if our findings are confirmed, genetic correlation should follow.

Introduction. Elevated pulmonary arterial pressure (PAP) is considered a relative contraindication to the treatment of pulmonary arteriovenous malformations (PAVMs) by embolisation. We aimed to examine PAP distribution and contributory factors in individuals with PAVMs, and to establish whether embolisation increases the PAP, in particular in individuals with pre-existing pulmonary hypertension. Methods. PAP were recorded prior to contrast injection in 143 individuals with PAVMs undergoing angiography for PAVM embolisation. 131/143 (92%) had underlying HHT. 35/143 individuals had measurements in consecutive embolisation session at mean interval 19.9 (range 2-121) months. 20/143 individuals with pre-existing elevated PAP mean had same-session pre and post embolisation measurements. Results. The mean PAP mean was 14.00±5.01 mmHg (range 6-40 mmHg). Of the five individuals with mean PAP >25mmHg, three had severe left ventricular disease and/or mitral valve pathology, and two had idiopathic pulmonary hypertension. PAP was significantly correlated with age ($p<0.0001$, Spearman rank; $r=0.004$, multiple regression analyses with overall $p<0.0001, r^2=15.89\%$). We are currently examining other potential contributory factors. Overall, there was no significant increase in PAP mean as a result of embolisation, even in patients with initial PAP mean in the upper quartile (>16 mmHg). In half of this group, embolisation led to a fall in PAP mean; the maximum rise was 4 mmHg in the same session, and 8mmHg in sequential angiography sessions 3-80 (mean 26.7) months apart. Conclusion. PAP increases with age in individuals with PAVMs. Significant increases as a result of PAVM embolisation were not observed in this series.

We thank the families and friends of HHT patients whose donations supported this work.
and 11-2006 underwent a transthoracic contrast echocardiography (TTE) for detecting PAVM. All patients received a structured headache questionnaire. Two neurologists diagnosed migraine according to International Headache Society criteria. Results. One-hundred and ninety-nine subjects (63% female, mean age 44.7±14.2 years) completed the questionnaire. A PAVM was present in 36%. The overall prevalence of migraine was 23% (13% in male, 29% in female; p=0.01) and MA 10% (7% in male, 12% in female; p=0.25). In patients with a PAVM the prevalence of overall migraine was 21% compared to 24% in patients without PAVM (p=0.68), with no association between the size of the shunt and overall migraine. The prevalence of MA was 16% in patients with a PAVM compared to 8% in those without a PAVM (p=0.06). MA occurred in 28% in patients with a large shunt (>100 bubbles), 21% in patients with a at least a moderate shunt (>20 bubbles), and 10% in the presence of a small shunt (<20 bubbles) (p for trend is 0.005). Kappa coefficient for interobserver reliability was 0.9 (p < 0.001).

Conclusion: Only MA seems to be associated with the presence of PAVM, and the prevalence of MA increases with increasing size of the pulmonary shunt.

**090**

**DIFFUSE PULMONARY ARTERIOVENOUS MALFORMATIONS IN HHT SUCCESSFULLY TREATED BY REPEATED TRANSCATHETER OCCLUSION. CASE REPORT AND LITERATURE REVIEW**

M.F. Carette, A. Parrot, A. Bellocq, A. Khalil
Centre d’Accueil de la Maladie de Rendu Osler de Tenon (CAMROT); AP-HP, Tenon hospital, Paris, France

**Aim.** To report the case of a patient with HHT history and diffuse PAVM successfully treated by repeated TCO. Material and Methods. We reviewed the chart, imaging studies and biological study stressing on PaO₂, SaO₂ measurement before and during the follow-up after each TCO sessions (Table 1). Results. A 25-year-old woman presented at 27 weeks gestational age (GA) with sudden onset of right leg weakness during 20mn with complete regression. HHT was diagnosed on the association of epistaxis, telangiectasia, family history and furthermore still known PAVMs responsible for dyspnea. Unenhanced, chest CT and MR, showed a large right upper lobe PAVM. It was occluded by TCO (S1) to prevent stroke recurrence. After a transient improvement of dyspnea, a worsening with decreased of PaO₂ led to a cesarean section at GA of 35.5 weeks. At this time, a thoracic angio-MDCT showed multiple PAVMs and acute pulmonary embolism. In spite anticoagulation, dyspnea worsened. Two sessions of TCO were performed (S2, S3) complicated by multiple pulmonary infarcts and without improvement of PaO₂. Another evaluation, before subscription on lung transplantation list, always showing numerous smalls PAVMs, we try a new TCO (S4) occluding 12 smalls PAVMs which improved dramatically the PaO₂. So two other sessions were performed (S5, S6) leading to improve PaO₂, to stop the nasal oxygen, without pulmonary hypertension (8/1- 4 mmHg). Conclusions. In spite of a very bad prognosis, according to the literature review, for diffuse PAVMs, this case illustrate the possibility to treat them successfully, but with multiple sessions.

**Table 1: PaO₂ and SaO₂ at Room air evolution and oxygeno-therapy needed before and after each Transcatheter Occlusion (TCO) session of pulmonary arteriovenous malformation (PAVM).**

<table>
<thead>
<tr>
<th>Table 1: PaO₂ and SaO₂ at Room air evolution and oxygene-therapy needed before and after each Transcatheter Occlusion (TCO) session of pulmonary arteriovenous malformation (PAVM).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session (n°) / Number of PAVM Occluded (total length)</td>
</tr>
<tr>
<td>S1 / 201</td>
</tr>
<tr>
<td>S2 / 3.IV / 2.5</td>
</tr>
<tr>
<td>S3 / 10.IV / 2.5</td>
</tr>
<tr>
<td>S4 / 15.V / 4</td>
</tr>
<tr>
<td>S5 / 12.VI / 5</td>
</tr>
<tr>
<td>S6 / 20.XI / 10</td>
</tr>
</tbody>
</table>

**091**

**RESULTS AND ADVERSE EVENTS OF TRANSCERVICAL EMBOLIZATION OF PULMONARY VASCULAR MALFORMATIONS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA**

M. Grosso,¹ F. Pedrazzini,² E. Buscarini,³ C. Olivieri,³ C. Danesino,² P. Gazzaniga,² L. Reduzzi,² V. Portugalli,³ F. Pagella,³ G. Pongiglione,³ E. Boccardi,³ on behalf of HHT-NET

¹Radiology Dept, Ospedale S Croce, Cuneo; ²Gastroenterology Dept, Maggiore Hospital, Crema; ³Genetic Institute, University of Pavia; ⁴Cardiology Dept, ⁵Radiology Dept, Maggiore Hospital, Crema; ⁶ENT Institute, University of Pavia; ⁷Pediatric Cardiology Dept, Ospedale Gaslini, Genova; ⁸Interventional Neuroangiology Unit, Niguarda Hospital, Milan, Italy

**Aim.** To review results and adverse events of transarterial embolization of pulmonary vascular malformations (PAVMs) in hereditary hemorrhagic telangiectasia (HHT). Methods. In the context of the multidisciplinary HHT family screening protocol of HHT-NET in the period 1/2001-12/2006 28 HHT patients (14 males, mean age 50.3, range 19-75) with PAVMs were sent to our unit. Patients underwent transarterial embolization; occluding material employed were amagnetic coils or Amplatzer plug. Oxygen saturation before and after embolization procedure were recorded. All patients had enhanced multislice chest CT at 6 months and one year to judge completeness of PAVM occlusion. Appropriate clinical and CT follow-up or re-treatment was advised after the one-year check. Adverse events related to embolization, either immediate or delayed, were recorded. Results. 58 PAVMs were treated in 28 patients with 33 procedures. Metallic coils were used in 32 procedure, Amplatzer plug.
in 1. Mean oxygen saturation before embolization was 93 (SD 4%), and after it was 97 (SD 2%). In a mean follow-up of 18.7 months (range 1-71) complete occlusion of all treated lesions without any recanalization; 3 patients underwent re-treatment for 4 newly appeared or enlarged PAVMs. All patients were discharged the day after the procedure, except for 1 patient (1/33 procedures, 3%) who had an ischemic stroke, requiring 6 further days of hospitalization. No immediate or delayed device dislocation were found. Conclusion. Our experience confirms effectiveness and safety of transarterial embolization for treatment of PAVMs in HHT.

092

PATIENT FORAMEN OVALE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A PREVALENCE STUDY WITH CONTRAST ECHOCARDIOGRAPHY

P. Gazzaniga,1 L. Lanzarini,2 S.C. Mancini,1 E.Buscarini,1 G. Manfredi,1 C. Danesino,2 C. Olivieri,2 L. Reduzzi,2 R. Dore,2 P. Blotta,1 F. Pagella,1 M. Grosso,4 G. Pongiglione,6 E. Boccardi,9 on behalf of HHT-NET

1Cardiology Dept, Ospedale Maggiore, Crema; 2Cardiology Dept, University of Pavia; 3Gastroenterology Dept., Crema; 4Genetic Institute, University of Pavia; 5Radiology Dept, Crema; 6Radiology Dept, University of Pavia; 7ENT Dept, Crema; 8ENT Institute, University of Pavia; 9Interventional Neuroradiology Unit, Niguarda Hospital, Milan, Italy

Background. Contrast Echocardiography with second harmonic imaging (CE) has been shown to be a very sensitive test for the detection of PAVMs in Hereditary Hemorrhagic Telangiectasia (HHT). Patent Foramen Ovale (PFO) is a quite common finding in the healthy population and is often found in young patients with an unexplained cerebrovascular event. CE is widely employed to detect right to left shunt in patient with suspected PFO. Aim of this study was to detect the prevalence of PFO in HHT. Methods. In the context of our multidisciplinary HHT family screening protocol 302 consecutive subjects were screened for PAVMs with CE. A positive finding for the diagnosis of PAVMs was defined as the appearance of any bubbles in the left atrium later than 3 cardiac cycles after initial opacification of the right chambers. A PFO was diagnosed if at least one microbubble was detected in the left atrium within three cycles following the appearance of the contrast in the right atrium. Valsalva manoeuvre was not performed. All patients had multislice chest CT. Results. 16 patients, 5.3%, had positive CE for intracardiac right-to-left shunt; 2 of them had positive CT scan for PAVMs. Conclusion. In HHT families an analogous prevalence of PFO was found, during normal respiration, as compared with literature data regarding healthy subjects. Its potential misleading role in the echocardiographic screening of PAVMs will be discussed.

093

THE PREVALENCE OF HEPATIC CYSTS IN FAMILIES WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA

E. Buscarini,1 G. Manfredi,1 C. Olivieri,2 C. Danesino,2 P. Gazzaniga,1 P. Blotta,4 P.A. Forner,1 L. Reduzzi,2 V. Portugalli,1 F. Pagella,1 M. Grosso,4 G. Pongiglione,6 E. Boccardi,9 on behalf of HHT-NET

1Gastroenterology Dept, Maggiore Hospital, Crema; 2Genetic Institute, University of Pavia; 3Cardiology Dept, 4ENT Dept, 5Radiology Dept, Maggiore Hospital, Crema; 6ENT Institute, University of Pavia; 7Radiology Dept, Ospedale S Croce, Cuneo; 8Paediatric Cardiology Dept, Ospedale Gaslini, Genova; 9Interventional Neuroradiology Unit, Niguarda Hospital, Milan, Italy

Aim. to determine the prevalence of liver cysts in HHT families (either in non- or in affected subjects) as determined by Doppler ultrasound (US) screening, and to compare with prevalence in general population. Methods. In our familial screening protocol for HHT we searched in all subjects for hepatic VMs and other abnormalities including focal liver lesions; typical simple cysts with no oncology history were assessed on the basis of Doppler US as for number, and size. Abdominal US scans of 1878 cases from general non-HHT population referred to our Department during the period January to December 2006 were reviewed for the presence of hepatic cysts. Statistical associations were established by comparative analysis with prevalence of liver cysts in HHT families, in non- and in affected subjects, in affected subjects with liver VMs, with different severity grading of hepatic VMs from 0+ to 4, and in general population (2 with Yates correction). Results. Four hundred and eightythree subjects underwent our screening protocol; 335 proved to be affected, in 151 liver VMs were showed, 102 of them of grade 0+/2, and 49 of grade 3/4. Prevalence and characteristics of liver cysts are given in Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Liver VMs</th>
<th>Liver VMs</th>
</tr>
</thead>
<tbody>
<tr>
<td>grades 0+2</td>
<td>grades 3/4</td>
</tr>
<tr>
<td>affected + liver</td>
<td>2/3</td>
</tr>
</tbody>
</table>

No difference proved statistically significant. Conclusions. Prevalence of hepatic cysts in HHT families is similar to that found in general population; liver cysts do not show a significant correlation with liver VMs.
MIGHT THERE BE ANY PLACE FOR SURGICAL RESECTIVE APPROACH OF INTRAHEPATIC ARTEROVENOUS MALFORMATION COMPLICATING HEREDITARY HEMORRHAGIC TELANGIECTASIA? REPORT OF A CASE

G. Orlando, C. Saba, C. Scelzo, J. Lerut, G. Tisone
Transplant Unit, Surgical Clinic, S. Eugenio Hospital, Tor Vergata University of Rome, Italy; 1Department of Internal Medicine, University Interdepartmental HHT Center, University of Bari, Italy; 2Department of Surgery, Liver Transplant and General Surgery, Catholic University of Leuven, Belgium; 3School of Medicine, Tor Vergata University of Rome, Italy

A 55-year old woman suffering from hereditary hemorrhagic telangiectasias (HHT) underwent a left lateral liver bisegmentectomy (segment 2 and 3) for a giant arterovenous malformation (AVM) connecting the left hepatic artery to the portal system. This lesion was responsible for progressive fatigue and invalidating effort dyspnoea. Recurrent epistaxis, diffuse telangiectasias and ecchymoses were also present. Transarterial embolization of the feeding artery was excluded for the large calibre of the vessel, whose occlusion would have entailed a high risk of biliary necrosis with sepsis. Postoperative course was uneventful and patient is doing well, three years after the operation. A comprehensive screening for HHT did not reveal any sign of recurrence of the AVM. To our best knowledge, this is the first case of hepatic-based HHT treated with liver resection. The main matter of concern is the risk of relapse. If future studies will demonstrate that the intra-hepatic relapse of AVM is the rule, we will have two options: to neglect pre-emptive surgery, as it would represent a major surgical risk factor for future transplantation; to perform surgery anyway, when patients are followed in centres having a small volume of activity where the waiting time on list is long. On the other hand, if it will be proven that the ablation of AVM is effective and is not followed by local recurrence, then the role of surgery might become prominent. This anecdotal report should promote this approach in order to define its future role in the treatment of this rare disease.

ARE THERE MORE ABDOMINAL VASCULAR ANATOMIC VARIANTS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA?

J.A. Parra, J. Bueno, R. Zarrabeitia, A. Pérez del Molino, M.C. Fariñas, M.T. Delgado
1Hospital Universitario Marqués de Valdecilla, 2Hospital Santa María de la Sierra Llanza, 3Universidad de Cantabria, Cantabria, Spain

Aim. To evaluate the incidence of abdominal vascular anatomic variants in patients with HHT. Material and Methods. 50 patients (21 men and 29 women, mean age, 47.3 years) with 2 (one patient), 3 (26 patients) and 4 (23 patients) criteria for HHT with a 2 MDCT performed to rule out vascular malformations in the abdomen. 28 out of 50 patients also had a genetic test and according to it 24 were type II and 4 type I HHT. All MDCT scans were made in arterial and portal phase with 3 mm section and 1 mm reconstruction thickness and were reviewed for two radiologists independently. Results. Vascular anatomic variants were observed in 35/50 (70%) patients. 22/35 (63%) in the origin of the hepatic artery, 63% in renal vascularization and 17% at the portal level. The two most frequent hepatic artery anatomic variants were a left hepatic artery originated directly in the celiac trunk, and a right hepatic artery originated from AMS. Two or more right or left renal arteries were the most frequent anatomic variants in the kidney. A left portal vein originated in the right portal vein was the most frequent anatomic variant in the portal system. According to the genetic test 77% of type II and 75% of type I HHT present vascular anatomic variants. Conclusions. Abdominal vascular anatomic variants are more frequent than previously described in patients with HHT. Vascular anatomic variants are seen in both genetic types of HHT.
097
ESOPHAGO-GASTRO-DUODENAL LESIONS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA

A. Pisani, M. Principi, P. Suppressa, G. Pasculli, A. Di Leo, A. Francavilla, C. Sabbà

Department of Gastroenterology, Department of Internal Medicine, Interdepartmental HHT Centre, University of Bari, Italy

Aim. To evaluate the prevalence and clinical behaviour of esophago-gastro-duodenal TAs in a cohort of 80 HHT patients. Methods. Over a three-year-long period, esophago-gastro-duodenoscopy (EGDS) was performed in 80 (41 M, 39 F; mean age 49.65 yrs; range 19-75 y) consecutive HHT patients with definite diagnosis. The patients were screened independent of the presence of gastric symptoms or upper gastrointestinal bleeding. Results. EGDS was without complications in all 80 subjects, 48 of whom (60%) (Group A) had esophago-gastro-duodenal TAs and 32 (Group B) without. All of Group A had TAs in the stomach accompanied by duodenal TAs in 18 patients (22.5%) and esophageal TAs in 3 patients (3.7%). Moreover, 7/48 patients had bleeding gastric TAs during EGDS treated successfully with Argon Plasma Coagulator. An additional 9/48 patients with gastric TAs without active bleeding at EGDS also had melena (2 also with hematemesis). The latter 16 pts (33.3%) required blood transfusions during the observation; in the 9 patients without bleeding during EGDS, probably bleeding was due to lower intestinal involvement. Regarding liver involvement in Group A, 40 pts were hepatic AVM+ and 8 pts were hepatic AVM-. Mean age was 55.7 years. In Group B, 12/32 patients (37.5%) required transfusions due to epistaxis, present in all but one patient’s history. The 32 patients were: 18 hepatic AVM+ and 14 hepatic AVM-. Mean age was 43.1 years. Conclusions. A strong association was found between gastric TAs (48 pts) and hepatic AVMs (40 pts) in Group A, while in Group B, the incidence of hepatic (18 pts) was similar. Esophago-gastro-duodenal TAs were more frequently found in older patients: in fact, Group A had a higher mean age than Group B. Thus, gastric and intestinal TAs might develop with age.

098
PERCUTANEOUS EMBOLIZATION IN 12 PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA AND SEVERE EPISTAXIS


St. Antonius Ziekenhuis, Nieuwegein, The Netherlands

Objective. Evaluation of the results of embolization in patients with hereditary hemorrhagic telangiectasia (HHT) because of severe epistaxis. A questionnaire was used about the frequency and severity of epistaxis, quality of life, haemoglobin 1 month before and 1 month/1 year after embolization. Patients and methods. Between November 1992 till July 2006 all patients with definite HHT and embolization were asked to participate in this retrospective study. During this period 18 patients had one or more procedures. Included were 12 patients (6 males, 6 females, aged 43–75 years, mean 55.1±8.2) with a total number of 19 embolizations. 6 Patients were excluded; one died of an indirect complication of the embolization. Intervention. Percutaneous transfemoral catheterization and angiography of the internal maxillary arteries. Embolization of the most distal branches with polyvinyl alcohol particles or microcoils on the site of the abnormal vessels. Results. In 18 embolizations the impact (daily frequency x severity in 3 grades) of epistaxis improved the first month. After one year 11 embolizations led to subjective improvement of nosebleeds. Mean haemoglobin rose from 6.3 to 7.2 mmol/L after 1 year. Quality of life did improve in 13 embolizations and was equal in 6 embolizations. Conclusion. The direct effect of the embolization is satisfactory, but temporarily in 58%. The indication should be made carefully, because there are possible major complications.

099
ANALYSIS OF MORPHOLOGY AND DISTRIBUTION OF NASAL TELANGIECTASIAS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA PATIENTS


*Otorhinolaryngology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; *Paediatric Cardiology Department, Hospital Gaslini, Genova, Italy; *Radiology Unit, Santa Croce Hospital, Cuneo, Italy; *Cardiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; *Radiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; *Genetic Institute, University of Pavia, Italy; *Gastroenterology Unit, Maggiore Hospital, Crema, Italy

Intranasal pattern and distribution of telangiectasias in Hereditary Hemorrhagic Telangiectasia (HHT) patients are variable. From 1996 to 2006, 161 HHT patients were evaluated at ENT unit of Fondazione IRCCS Policlinico San Matteo in Pavia. We analyzed morphology and distribution of these lesions in 65 patients with epistaxis before treatment by argon plasma coagulation. The patient group comprised 37 males and 28 females. The age ranged from 19 to 79 years (mean 52.2 years; median 54 years). All patients were diagnosed as affected by HHT according to the Curaçao criteria. No-one of the patients previously had undergone septodermoplasty. All patients underwent fiberoptic examination of nasal fossae. We classified distribution of telangiectasias defining six sites: nasal valve, anterior nasal septum, posterior nasal septum (considering as anterior limit a coronal plane tangential to the head of middle turbinates), inferior turbinates, middle turbinates, floor of nasal fossae. For every site we defined the presence or absence of telangiectasias and the pattern (punctate telangiectasias, interconnected punctate telangiectasias, large isolated telangiectasias, large interconnected telangiectasias). Only anterior nasal septum and inferior turbinates resulted affected in 100% of patients. Floor of nasal fossae, nasal valve and posterior nasal septum were the sites with reduced presence of telangiectasias. No significative difference resulted between different age groups considering morphology and distribution of telangiectasias.
100

2-YEARS FOLLOW-UP IN HEREDITARY HEMORRHAGIC TELANGIECTASIA PATIENTS TREATED BY ARGON PLASMA COAGULATION WITH LOCAL ANESTHESIA

F. Pagella,1 A. Colombo,1 E. Matti,1 L. Semino,1 G. Giourgos,1 G. Pongiglione,1 M. Grosso,1 L. Lanzarini,2 R. Dore,3 C. Olivieri,3 E. Buscarini,3 F. Miller,3 G. Pongiglione,1 C. Danesino1

‘Otorhinolaryngology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Paediatric Cardiology Department, Hospital Gaslini, Genova, Italy; ‘Radiology Unit, Santa Croce Hospital, Cuneo, Italy; ‘Cardiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ‘Radiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ‘Genetic Institute, University of Pavia, Italy; ‘Gastroenterology Unit, Maggiore Hospital, Crema, Italy

Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) patients is caused by vascular dysplasia leading to telangiectasias involving nasal mucosa. Over the years, various treatment modalities for epistaxis associated with this disease have been described, but there is still no general agreement upon the best treatment. From 1996 to 2006, 115 HHT patients were treated at ENT unit of Fondazione IRCCS Policlinico San Matteo in Pavia. 91 of these patients were treated by argon plasma coagulation (APC). In early 2005 we presented preliminary results in 43 patients with diagnosed HHT according to the Curaçao criteria who underwent treatment by APC between 1997 and 2004. In that study 36 patients (83.7%) reported substantial reduction of bleeding after treatment. Duration of improvement was six months in 15 patients, from 3 to 6 months in 12 patients, and less than 3 months in 9 patients. We present our data of 2-years follow-up in those 43 patients to evaluate long term results in treatment by APC. 24 months after treatment 8 of 15 patients who reported a significative improvement at 6-month questionnaire declared a persisting reduction of bleeding. During the 24-months follow-up 7 of 43 patients requested one additional treatment by APC. 1 patients requested two additional treatments. 3 patients with epistaxis disagreed to undergo the same surgery. APC isn’t a definitive treatment of epistaxis in HHT patients but can provide good short-term results reducing bleeding and need for blood transfusion. Our experience suggests that in some patients this modality of treatment can provide also good long-term results. More investigations are needed to clarify the reasons of different results between patients and the eventually predictive factors useful to better formulate indication for APC.

101

EXPERIENCE WITH YOUNG’S PROCEDURE FOR THE MANAGEMENT OF EPISTAXIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA

L.P. Johnson,1 F. Miller,1 T.M. Davidson2

1Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT; 2Department of Radiology, University of Utah Health Sciences Center, Salt Lake City, UT; University of California at San Diego, San Diego, CA; 3Division of Otolaryngology-Head and Neck Surgery, University of California at San Diego, San Diego, CA, USA

Young’s procedure, or surgical closure of the nostril was first described by Taylor and Young in 1961 for management of atrophic rhinitis. The procedure was first proposed as a treatment for epistaxis in hereditary hemorrhagic telangiectasia by Hosney and Innes in 1994, and by Gluckman and Portugal in that same year. This procedure has more recently been described by Valerie Lund and Howard in 1997, for management of severe epistaxis in patients with hereditary hemorrhagic telangiectasia. This presentation describes the experience using Young’s procedure in four patients at the University of Utah HHT Center and in one patient at the University of California, San Diego HHT Center. The surgical technique for the procedure, as well as the patient profiles and results will be presented. The first patient underwent surgery in May, 2005 and to date, all patients have had cessation of the epistaxis and are now able to maintain a normal hematocrit without their previous transfusion dependency. Young’s procedure is an effective surgical treatment for the epistaxis in hereditary hemorrhagic telangiectasia in a select group of patients in whom previous treatments have not been effective in managing the epistaxis and anemia.

102

COMBINED EMBOLIZATION AND LASER TREATMENT OF EPISTAXIS IN HHT PATIENTS

M.L. Fiorella, C. Russo, R. Fiorella

Ophthalmology and Otolaryngology Department and HHT Center, University of Bari, Italy

Severe epistaxes are common in HHT patients and several methods have been described in the literature for their control. One of the most recent treatments is selective embolization of nasal arteries; in this technique small particles are injected into the arteries in order to occlude the vascular bed as distally as possible. Endovascular embolization has been reported in the literature as being efficient, safe and eventually repeated in the case of recurrent bleeding. The aim of this study is to present the results of a combined treatment with selective embolization of nasal arteries in general anesthesia to obliterate most of the vessels followed, after 24 hours, by laser coagulation of residual telangiectases in local anesthesia. A pilot study was performed in four HHT transfusion-dependent patients affected with daily nosebleeds, and post-treatment results were evaluated by means of pre- and post-operative haemoglobin levels and a questionnaire. All patients demonstrated a reduction in the duration and
number of episodes resulting in an increase of haemoglobin levels after the combined treatment. No negative side-effects of the treatment were observed. In conclusion, this combined technique permitted to improve patients’ quality of life. Further studies are necessary to confirm this preliminary report on a limited number of cases.

103 THERAPY FOR EPISTAXIS WITH RALOXIFEN IN HEREDITARY HEMORRHAGIC TELANGIECTASIA


Unidad HHT; Hospital Sierrallana & Hospital Universitario Marqués de Valdecilla, Cantabria; Centro de Investigaciones Biológicas, CSIC, Madrid; Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

Aim. Based on previous reports about good response of epistaxis to tamoxifen, an oestrogen receptor modulator, we assessed the efficacy of raloxifen (a drug of the same group, with advantages on bone mineralization, cardiovascular and gynecological cancer prevention), in postmenopausal HHT women with osteoporosis, for epistaxis management. Methods. During the last year, eleven HHT postmenopausal women diagnosed of osteoporosis received daily oral treatment with 60 mg raloxifen. Effects of the treatment were observed. In conclusion, this study. Prevention and care of dento-alveolar diseases are indicated due to the risk of systemic infective complications; osteitic foci are often the site of septic emboli which are responsible for potentially lethal intracranic infections. Forty-three patients (55%) showed carious lesions; osteitic foci are often the site of septic emboli which are responsible for potentially lethal intracranic infections. Forty-three patients (55%) showed carious lesions. Discussion. Raloxifen may be useful in the management of epistaxis offering a wide spectrum of indications and benefits. Further randomised trials in HHT with selective estrogen receptor modulators should be considered.

104 QUALITY OF LIFE AND EPISTAXIS IN HHT; EFFECT OF TREATMENT


St. Antonius Hospital, Nieuwegein, The Netherlands

Introduction. This study investigates the relation between epistaxis and quality of life. (Quol) and the effect of treatment. Methods. An anonymous postal questionnaire was sent to 345 patients over 18 years with definite HHT. Patients who participated in trials for epistaxis (n=79) had been excluded. Questions about frequency and severity of nosebleeds and Quol (scale 0-10) were asked before and after treatment. Results. 200 patients (58%), 124 women, 47.5 years, returned the questionnaire; 33% had daily, 28% weekly, 31% monthly, 4% yearly and 5% no epistaxis. 17% had minor (few drops), 45% moderate (many drops) and 38% severe (gush) epistaxis. Quol was insufficient (grade 0-5) in 17%, moderate (6-7.5) in 17% and good (8-10) in 66%. Quol and impact (annual frequency x grade of severity) of epistaxis correlated significantly (p<.001). 64 (32%) patients with more severe HHT (Quol 8-10 in 43%) had an average of 7.7 local treatments. Treatment had beneficial influence on Quol (p=0.03), and not significantly on annual frequency (p=0.21) and impact (p=0.14) of epistaxis. This benefit has disappeared at the time of the questionnaire (mean 17.5 years later). Electrocautery (n=33), laser treatment (n=22), dermoplasty (n=7) caused a non-significant initial improvement of Quol, annual frequency and impact of epistaxis. Significance did not improve after exclusion of bowel-HHT (n=16) and the use of anticoagulants (n=11). Also, treatment had no influence on iron-suppletion and transfusions. Comment. Quol and epistaxis are significantly related. Quol is affected only temporarily by treatment. Quol is high. Due to selection?

105 DENTAL CARE OF HHT PATIENTS: CLINICAL AND SURGICAL MANAGEMENT OF 78 CASES

V. De Falco1, V. Crincoli1, M. Scivetti1, G. Pasculli2, G. D'avanzante1, C. Sabbia2, G. Favia3

University of Bari, Interdepartmental HHT Center;1 Unità Operativa Complessa di Odontoiatria;2 Dipartimento di Medicina Interna e Medicina Pubblica, Bari, Italy

Seventy-eight HHT patients recruited during the period 2003-06 from the HHT center in Bari were considered in this study. Prevention and care of dento-alveolar diseases are indicated due to the risk of systemic infective complications; osteitic foci are often the site of septic emboli which are responsible for potentially lethal intracranic infections. Forty-three patients (55%) showed carious disease, 20 (25%) periapical lesions, 24 (31%) parodontopathies and 16 (20%) dysodontiasis. Seven patients had a history of cerebral abscesses, six of whom were associated to the presence of acute and chronic dento-alveolar infections. Therefore, in our experience, we believed that surgical management in these patients would be a safer choice rather than a doubtfully-successful conservative treatment. All patients underwent a clinical protocol including intra- and extra-oral clinical examination, dental orthopantomograms, oral hygiene protocols (scaling, root planning), care of parodontal lesions, and restorative, endodontic and surgical treatments. We confirm the relevance of dental prophylaxis and its inclusion in the routine management of HHT patients.
106

**JUVENILE STROKE IN A CASE OF JUVENILE POLYPOSIS-HEREDITARY HAEMORRHAGIC TELEANGIECTASIA**

S. Mazzucco, B. Bonetti, M. Ferrarini, G.M. Fabrizi, N. Rizzuto

*Department of Neurological and Visual Sciences, Section of Clinical Neurology, University of Verona, Italy*

A 28-year-old man was admitted to the hospital for acute occurrence of confusion, dysphasia and sensory disturbance at the right hand, in 2000. A brain CT demonstrated an hypodense left thalamic lesion. A subsequent brain MR disclosed an associated ipsilateral cortical frontoparietal lesion. A pituitary adenoma 1 cm of diameter was also seen. Genetic and acquired prothrombotic conditions were ruled out. A trans-esophageal echocardiogram suggested a possible extracardiac source of a right-to-left shunt. Chest TC confirmed the presence of a 3 cm diameter artero-venous fistula within the right inferior pulmonary lobe. The patient underwent percutaneous embolization of the fistula. Two years later, during a second procedure carried out in order to treat a recrudescence of the right inferior lobe fistula, a second one, previously overlooked, was discovered in the left inferior pulmonary lobe and subsequently treated in a separate session. The patient was diagnosed as having a juvenile polyposis (JP) when he was eighteen after a bowel bleeding due to a benign polyp of the sigma, which was endoscopically excised. The patient’s father died of colorectal cancer, like his brother; the patient had three sibs, two affected sisters and one apparently unaffected brother. The latter had had a hepileptic seizure a few years before. The patient was recently (in 2006) seen in our department for assessment of residual right-to-left shunt by means of TCD examination, which revealed a large permanent shunt. The suspect of JP-HHT was proposed and genetic testing for SMAD 4 gene mutations is ongoing.

107

**HHT FOUNDATION INTERNATIONAL: TODAY’S VISION IS TOMORROW’S REALITY**

M.S. Clancy

*Executive Director, HHT Foundation International*

The HHT Foundation serves as the International nexus for HHT education, support and research for patients and families affected with Hereditary Hemorrhagic Telangiectasia. The mission of the HHT Foundation International is find a cure for HHT while saving the lives and improving the well-being of individuals and families affected with HHT. To achieve this mission, the HHT Foundation International will: fund research to find better treatments and a cure; educate families and physicians about HHT so that awareness of crucial diagnosis and available treatments prevents needless disability and death; provide linkages between people affected by HHT; collaborate with multidisciplinary HHT Treatment Centers worldwide while advocating for patient access to these Centers; advocate for and support those with HHT while increasing public, private and governmental awareness of the disorder, engage the scientific and medical community so that talented individuals dedicate efforts toward advances in HHT screening, diagnosis, treatment, and research. Since 1991, the HHT Foundation has evolved into a dynamic and focused organization that has achieved crucial milestones and an unprecedented level of accomplishments. Every one of the Foundation’s activities is directed to the mission of the Foundation: Education and Support, Research and Advocacy.